HUP0400115A3 - Pharmaceutical composition for the intramuscular administration of fulvestrant - Google Patents

Pharmaceutical composition for the intramuscular administration of fulvestrant

Info

Publication number
HUP0400115A3
HUP0400115A3 HU0400115A HUP0400115A HUP0400115A3 HU P0400115 A3 HUP0400115 A3 HU P0400115A3 HU 0400115 A HU0400115 A HU 0400115A HU P0400115 A HUP0400115 A HU P0400115A HU P0400115 A3 HUP0400115 A3 HU P0400115A3
Authority
HU
Hungary
Prior art keywords
fulvestrant
pharmaceutical composition
intramuscular administration
intramuscular
administration
Prior art date
Application number
HU0400115A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0400115A2 publication Critical patent/HUP0400115A2/hu
Publication of HUP0400115A3 publication Critical patent/HUP0400115A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HU0400115A 2001-07-07 2002-07-03 Pharmaceutical composition for the intramuscular administration of fulvestrant HUP0400115A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (2)

Publication Number Publication Date
HUP0400115A2 HUP0400115A2 (hu) 2004-06-28
HUP0400115A3 true HUP0400115A3 (en) 2005-11-28

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400115A HUP0400115A3 (en) 2001-07-07 2002-07-03 Pharmaceutical composition for the intramuscular administration of fulvestrant

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP2417975A4 (en) 2009-08-31 2012-11-14 Xi An Libang Medical Technology Co Ltd FULVESTRANT NANOPERLENES / MICROPERLES AND MANUFACTURING METHOD AND USE
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
EP3441073B1 (en) * 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3466430B1 (en) 2016-05-31 2020-04-29 FUJIFILM Corporation Pharmaceutical composition
JP7220712B2 (ja) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク. フルベストラント製剤とその使用方法
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
US12377049B2 (en) 2019-12-11 2025-08-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
CN118717660B (zh) * 2024-06-12 2025-02-28 湖州亚瑟制药有限公司 一种注射用氟维司群药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
JP2004534093A (ja) 2004-11-11
HUP0400115A2 (hu) 2004-06-28
IS7097A (is) 2004-01-05
EP1406662A1 (en) 2004-04-14
PL367624A1 (en) 2005-03-07
RU2004102393A (ru) 2005-03-27
NO20040047L (no) 2004-02-23
BR0210898A (pt) 2004-06-22
WO2003006064A1 (en) 2003-01-23
CO5560585A2 (es) 2005-09-30
AR037138A1 (es) 2004-10-27
IL159576A0 (en) 2004-06-01
CA2453111A1 (en) 2003-01-23
CN1553815A (zh) 2004-12-08
MXPA04000028A (es) 2004-05-21

Similar Documents

Publication Publication Date Title
HUP0204137A3 (en) Pharmaceutical composition comprising fulvestrant
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
IL161214A0 (en) Compositions for delivery of drug combinations
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
EP1407785A4 (en) MEDICAL COMPOSITIONS
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
GB0111597D0 (en) Pharmaceutical compositions
SI1395242T1 (en) Liquid pharmaceutical composition
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
IL159576A0 (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1398040A4 (en) MEDICAL COMPOSITION
GB0129117D0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
GB0114746D0 (en) Medicinal composition
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
GB2382302B (en) Pharmaceutical compositions
IL157411A0 (en) Pharmaceutical composition
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
GB0125061D0 (en) Pharmaceutical composition
HU0103049D0 (en) Pharmaceutical composition
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis